Loading...
electroCore, Inc.
ECOR•NASDAQ
HealthcareMedical - Devices
$4.82
$0.17(3.66%)
electroCore, Inc. (ECOR) Stock Overview
Explore electroCore, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
57.09%
↑ 57.09%
Profit Growth
$-1.79
↑ 36.89%
EPS Growth
$-1.79
↑ 53.51%
Operating Margin
-48.30%
↑ 35.33%
ROE
-144.22%
↑ 36.89%
Dividend Yield
0.00%
Analyst Recommendations
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
Price Targets
Low$0.00
Average$0.00
High$0.00
Company Profile
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
CEO
Mr. Daniel S. Goldberger
Employees
73
Headquarters
200 Forge Way, Rockaway, NJ
Founded
2018